EXOZ.US eXoZymes, Inc.

Healthcare Biotechnology USA Stocks
3.83 USD
Close of Nov 14, 2026
3.24 16.90
Market cap
USD 35.6M
P/E
-
P/B
10.19x
ROE
-455.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EXOZ.US undervalued?

Graham number

The Graham number of eXoZymes, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

eXoZymes, Inc. fundamental analysis

No fundamental analysis for eXoZymes, Inc. yet.

eXoZymes, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About eXoZymes, Inc.

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Full company profile